Foghorn Therapeutics (FHTX) Net Income towards Common Stockholders (2019 - 2026)

Foghorn Therapeutics' Net Income towards Common Stockholders history runs 8 years deep, the most recent figure standing at -$80.6 million for Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders fell 250.88% year-over-year to -$80.6 million; the TTM figure through Mar 2026 stood at -$226.0 million (down 167.22% YoY), while the FY2025 annual figure was -$265.3 million, down 206.26% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$80.6 million, down from -$23.8 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was -$14.3 million in Q3 2023, with the low at -$80.6 million in Q1 2026.
• The 5-year median for Net Income towards Common Stockholders is -$25.8 million (2022), against an average of -$31.9 million.
• The sharpest annual moves came in 2022 and 2026: Net Income towards Common Stockholders jumped 74.31% in 2022, then plunged 250.88% in 2026.
• Foghorn Therapeutics' Net Income towards Common Stockholders stood at -$28.9 million in 2022, then climbed by 16.55% to -$24.1 million in 2023, then advanced by 19.09% to -$19.5 million in 2024, then slipped by 22.28% to -$23.8 million in 2025, then plunged by 238.14% to -$80.6 million in 2026.
• Business Quant data shows FHTX's Net Income towards Common Stockholders at -$80.6 million in Q1 2026, -$23.8 million in Q4 2025, and -$41.8 million in Q3 2025.